Get started
Live feed
INSIDERFilingvia Quantisnow
Codiak BioSciences Inc. logo

Codiak BioSciences (CDAK) executive Mauro received 190,000 Stock Option (Right to Buy)

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

David J Mauro (executive at Codiak BioSciences Inc., CDAK) reported that they received 190,000 Stock Option (Right to Buy) on Jan 24, 2023.

Reporting person
Mauro David J

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Jan 24, 2023Grant or award (A)Stock Option (Right to Buy)On 190,000 Common Stock1+190,000--190,000 direct

Holdings before and after

  • Stock Option (Right to Buy): 0 to 190,000 direct

Footnotes from the filing

  1. 1. 25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Mauro report in this CDAK Form 4?

David J Mauro (executive at Codiak BioSciences Inc., CDAK) reported that they received 190,000 Stock Option (Right to Buy) on Jan 24, 2023.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for CDAK

Earlier insider filings at CDAK

Quantisnow market dataNASDAQ
Codiak BioSciences Inc. logo
CDAK
Codiak BioSciences Inc.
Market cap
30-day
Sector
Health Care
Industry
Medicinal Chemicals and Botanical Products
Listed since
2020
Get push alerts for CDAK

Follow CDAK and get a push notification the moment its next story breaks.

Full CDAK profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CDAK (Codiak BioSciences Inc.) and more on Quantisnow.